This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n16http://linked.opendata.cz/resource/mesh/concept/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01425/identifier/chemspider/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01425/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01425/identifier/pharmgkb/
n18http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01425/identifier/bindingdb/
owlhttp://www.w3.org/2002/07/owl#
n15http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01425/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01425/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB01425/identifier/drugbank/
n20http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01425
rdf:type
n3:Drug
n3:description
Alizapride is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.
n3:generalReferences
# Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M: Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. Cancer Chemother Pharmacol. 1988;22(4):316-20. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3048762
n3:group
approved
n3:halfLife
3 hours
n3:indication
Alizapride is used in the treatment of nausea and vomiting, including postoperative nausea and vomiting.
owl:sameAs
n11:DB01425 n18:DB01425
dcterms:title
Alizapride
adms:identifier
n6:39202 n7:DB01425 n8:50023804 n9:43008 n12:46505555 n13:PA164744894 n14:Alizapride
n3:mechanismOfAction
The anti-emetic action of Alizapride is due to its antagonist activity at D2 receptors in the chemoreceptor trigger zone (CTZ) in the central nervous system (CNS)—this action prevents nausea and vomiting triggered by most stimuli. Structurally similar to metoclopramide and, therefore, shares similar other atributres related to emesis and prokinetics.
n3:routeOfElimination
renal
n3:synonym
Alizaprida Alizapridum Plitican
n3:salt
n3:synthesisReference
Bulteau, G., Acher, J., Collignon, C. and Monier, J.C.; U S . Patent 4,039,672; August 2,1977; assigned to Societe D'Etudes Scientifiques et lndustrielles de I'lle-de-France.
n15:hasConcept
n16:M0105043
n3:IUPAC-Name
n4:271B4952-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4958-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4957-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4954-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4955-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4956-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4950-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4969-363D-11E5-9242-09173F13E4C5 n4:271B4951-363D-11E5-9242-09173F13E4C5 n4:271B494E-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B494F-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:A03FA05
n3:H-Bond-Acceptor-Count
n4:271B495E-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B495F-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4959-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B495A-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B495C-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B495B-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B495D-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
59338-93-1
n3:category
n3:Bioavailability
n4:271B4964-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4966-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4967-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4968-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4963-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4962-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4965-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4953-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4960-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4961-363D-11E5-9242-09173F13E4C5